human
enteroviru
positivestrand
rna
viru
belong
enteroviru
genu
picornavirida
famili
infect
predominantli
lead
hand
foot
mouth
diseas
hfmd
children
year
old
infect
resolv
spontan
howev
infect
occasion
caus
neurolog
complic
lead
cardiopulmonari
failur
death
outbreak
erupt
around
world
past
decad
mainli
appear
countri
region
asia
recent
year
hundr
case
involv
lethal
complic
report
outbreak
epidem
still
preval
asia
current
vaccin
antivir
drug
avail
use
infect
clinic
prevent
epidem
depend
upon
public
surveil
alon
recent
year
mani
effort
develop
drug
combat
infect
dozen
drug
report
show
activ
vitro
evalu
anim
model
includ
bovin
lactoferrin
ribavirin
sirna
type
interferon
although
drug
show
activ
infect
cell
line
anim
model
clinic
applic
yet
avail
lycorin
one
abund
alkaloid
amaryllidacea
wide
rang
biolog
effect
includ
apoptot
effect
tumor
cell
antimalari
effect
antiinflammatori
effect
induct
nausea
emesi
importantli
lycorin
also
shown
antivir
effect
human
immunodefici
viru
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
polioviru
coxsacki
viru
measl
viru
herp
simplex
viru
type
present
studi
activ
lycorin
replic
investig
vitro
mice
model
infect
strain
human
rhabdomyosarcoma
cell
rd
maintain
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
previous
describ
clinic
isol
strain
genbank
access
mouseadapt
strain
genbank
access
deriv
cultur
rd
cell
viru
titr
determin
use
plaqu
assay
describ
work
stock
viru
ml
prepar
experi
antivir
assay
rd
cell
cellswel
plate
plate
dmem
medium
lack
antibiot
grown
overnight
confluenc
rd
cell
infect
cultur
continu
dmem
medium
contain
fb
infect
cell
treat
lycorin
puriti
hplc
assay
nation
institut
food
drug
control
set
concentr
salin
infect
rd
cell
observ
cpe
harvest
eighthour
interv
post
infect
determin
number
viral
rna
copi
quantit
rtpcr
qrtpcr
half
maxim
inhibitori
concentr
defin
concentr
lycorin
caus
cpe
reduct
compar
salinetr
control
concentr
lycorin
requir
cell
cytotox
determin
rd
cell
describ
previous
briefli
rd
cell
plate
plate
grown
overnight
confluenc
cell
treat
lycorin
hour
set
concentr
defin
concentr
lycorin
caus
cpe
rd
cell
assess
express
viral
protein
follow
lycorin
treatment
rd
cell
cellswel
plate
plate
grown
overnight
confluenc
cell
infect
cultur
continu
hour
infect
cell
treat
lycorin
infect
rd
cell
harvest
wash
three
time
pb
ph
gibco
hour
treatment
harvest
cell
resuspend
pb
lyse
three
freezethaw
cycl
cell
debri
remov
centrifug
g
minut
supernat
subject
viral
rna
protein
analysi
infect
rd
cell
treat
salin
use
control
western
blot
assay
equal
amount
aliquot
supernat
separ
sdspage
transfer
onto
nitrocellulos
membran
immobilon
nc
millipor
franc
polyclon
mous
antibodi
viral
peptid
prepar
lab
dilut
primari
antibodi
visualis
hrpconjug
goat
antimous
secondari
antibodi
sigma
use
chemiluminesc
detect
system
santa
cruz
band
quantifi
densitometri
use
quantiti
one
softwar
intens
band
six
viral
protein
salinetr
group
use
standard
defin
densiti
band
viral
protein
lycorinetr
group
compar
respect
standard
qrtpcr
use
detect
viral
rna
copi
number
briefli
total
rna
isol
cultur
cell
tissu
mice
use
trizol
reagent
total
rna
revers
transcrib
use
random
hexam
reversetranscript
kit
promega
cdna
subject
quantit
pcr
quantitect
sybr
green
rtpcr
kit
qiagen
roch
light
system
cycl
primer
fragment
correspond
nucleotid
adjust
concentr
gradient
use
standard
calcul
copi
number
viral
rna
result
normalis
gapdh
semiquantit
rtpcr
use
confirm
result
qrtpcr
briefli
viral
cdna
obtain
assay
pcr
amplif
primer
result
normalis
gapdh
ten
elevendayold
icr
mice
provid
institut
laboratori
anim
scienc
peke
union
medic
colleg
anim
protocol
approv
institut
anim
care
use
committe
lethal
challeng
tendayold
mous
intraperiton
ip
inocul
lethal
dose
selflimit
model
develop
mous
elevendayold
inocul
via
ip
rout
hour
post
infect
infect
mice
intraperiton
inject
differ
concentr
lycorin
salin
daili
twice
day
placebo
group
inject
volum
salin
control
symptom
surviv
rate
infect
mice
monitor
daili
week
clinic
score
grade
follow
previous
describ
standard
muscl
tissu
mice
sampl
dpi
dpi
dpi
dpi
dpi
sent
virolog
patholog
analysi
experiment
group
six
mice
subject
patholog
examin
euthanasia
muscl
tissu
immedi
immersionfix
buffer
formalin
hour
tissu
bisect
embed
paraffin
stain
hematoxylin
eosin
stain
h
e
ten
section
muscl
observ
per
anim
blind
manner
immunohistochemistri
ihc
use
detect
virion
infect
tissu
describ
previous
briefli
section
incub
monoclon
mous
antibodi
millipor
dilut
hour
section
wash
three
time
pb
incub
hrpconjug
goat
antimous
igg
dilut
sigma
hour
section
develop
dab
observ
light
microscop
olympu
data
express
mean
sd
statist
signific
differ
mean
valu
assess
duncan
multiplerang
test
follow
oneway
analysi
varianc
anova
surviv
rate
analys
kaplanmei
analysi
p
valu
consid
signific
efficaci
lycorin
test
human
muscular
rd
cell
line
plaqu
reduct
assay
posit
control
ribavirin
determin
present
studi
similarli
lycorin
inhibit
infect
rd
cell
dosedepend
manner
figur
replic
figur
major
cpe
rd
cell
figur
significantli
inhibit
treatment
lycorin
lycorin
figur
rd
cell
approxim
higher
infect
studi
inhibitori
mechan
lycorin
infect
synthesi
sever
typic
viral
protein
detect
western
blot
hour
period
follow
lycorin
treatment
effect
inhibit
appear
figur
sequenti
translat
ntermin
ctermin
viral
polyprotein
viral
protein
synthesi
band
densiti
protein
hour
salinetreat
set
densiti
protein
hour
lycorinetreat
compar
salinetreat
respect
figur
inhibit
lycorin
synthesi
c
termin
protein
remark
n
termin
protein
inhibitori
rate
wherea
result
suggest
lycorin
affect
elong
viral
polyprotein
translat
util
mous
model
lethal
infect
evalu
effect
lycorin
inhibit
infect
placebotr
mice
develop
paralysi
dpi
die
within
dpi
treatment
ribavirin
mgkg
bodi
weight
enhanc
surviv
rate
infectedmic
meanwhil
lycorinetreat
dose
mgkg
prolong
surviv
time
mice
treatment
dose
mgkg
enhanc
surviv
rate
mice
respect
figur
result
reveal
mgkg
proper
dosag
dosag
use
analysi
effect
lycorin
experi
clinic
score
infect
mice
treat
placebo
lycorin
mgkg
systemat
evalu
treatment
lycorin
delay
paralysi
appear
day
later
compar
placebo
surviv
mice
lycorin
group
complet
recov
within
dpi
figur
mice
placebo
group
die
within
dpi
consist
result
clinic
score
surviv
rate
viru
replic
muscl
lycorinetr
mice
inhibit
fold
differ
time
point
compar
salin
control
detect
qrtpcr
semiquantit
rtpcr
figur
lycorin
treatment
also
obvious
reduc
amount
virion
muscl
tissu
compar
salin
control
immunohistolog
stain
figur
salinetr
group
seriou
muscl
necrot
appear
dpi
lead
paralysi
mice
lycorinetreat
mgkg
obvious
reduc
muscl
damag
caus
infect
figur
moder
inflamm
observ
muscl
tissu
lycorin
treat
mice
dpi
dpi
contrast
necrotis
myositi
placebotr
mice
dpi
dpi
mous
model
lethaldos
infect
use
imit
sever
complic
infect
patient
howev
infect
patient
lead
symptom
resolv
spontan
also
explor
effect
lycorin
moder
dose
infect
mice
suppos
imit
self
limit
patient
viru
replic
muscl
tissu
lycorinetr
mgkg
mice
significantli
inhibit
compar
salin
control
detect
qrtpcr
semiquantit
rtpcr
figur
salinetr
mice
develop
transient
ruffl
hair
paralysi
recov
within
day
lycorin
treatment
protect
infectedmic
symptom
paralysi
except
occasion
skin
fur
figur
result
indic
lycorin
treatment
abl
complet
protect
mice
obvious
symptom
upon
lowdos
challeng
along
broad
biolog
activ
capac
inhibit
replic
mani
differ
virus
confirm
lycorin
inhibit
infect
lycorin
show
inhibitori
activ
replic
rd
cell
lycorin
treatment
significantli
enhanc
surviv
rate
mice
demonstr
lycorin
may
potenti
drug
candid
clinic
treatment
infectioninduc
diseas
previou
studi
indic
lycorin
inhibit
protein
synthesi
eukaryot
cell
cellfre
system
protein
synthesi
catalys
eukaryot
ribosom
howev
debat
step
protein
synthesi
block
lycorin
jimenez
et
al
indic
lycorin
halt
protein
synthesi
eukaryot
cell
block
peptid
bond
format
lycorin
shown
prevent
coupl
nacetyl
leucyl
residu
uaccaacetyl
leucin
puromycin
therefor
postul
compound
inhibit
transpeptid
reaction
contrast
report
lycorin
affect
termin
elong
cleavag
polyprotein
singl
larg
code
region
genom
flank
untransl
region
utr
code
region
translat
singl
polyprotein
process
viral
proteas
yield
matur
viral
protein
includ
capsid
protein
nonstructur
protein
investig
inhibitori
mechan
lycorin
replic
detect
step
viral
life
cycl
initi
block
post
drug
treatment
found
repress
effect
lycorin
synthesi
viral
protein
locat
c
termin
polyprotein
earlier
substanti
effect
viral
protein
locat
n
termin
polyprotein
figur
therefor
conclud
drug
inhibit
elong
viral
polyprotein
protein
synthesi
imbalanc
synthesi
viral
protein
could
interrupt
packag
viru
inhibit
protein
could
result
reduct
replic
viru
protein
rna
polymeras
contrast
wide
rang
biolog
effect
lycorin
suspect
sourc
amaryllidacea
poison
human
anim
empir
data
previou
report
suggest
lycorin
may
respons
symptom
nausea
emesi
high
concentr
lycorineinduc
apoptosi
rd
cell
observ
studi
figur
indic
lycorin
noxiou
eukaryot
cell
howev
lycorin
could
inhibit
replic
low
concentr
inhibit
infect
approxim
lower
rd
cell
suggest
potenti
applic
clinic
treatment
infect
assumpt
verifi
evalu
antivir
effect
lycorin
mous
model
surviv
rate
mgkg
lycorinetr
mice
significantli
enhanc
compar
control
mice
upon
lethal
infect
figur
allevi
acut
symptom
reduct
patholog
chang
muscl
lycorinetr
mice
achiev
inhibit
replic
viru
figur
surviv
mice
lycorin
treat
group
recov
within
day
furthermor
lycorin
treatment
caus
obviou
side
effect
mice
test
dose
data
shown
follow
lethal
infect
lycorinetr
mice
surviv
rate
reach
salinetr
mice
die
within
dpi
figur
previou
studi
treatment
sever
drug
candid
includ
ribavirin
bovin
lactoferrin
sirna
type
interferon
abl
enhanc
surviv
rate
infect
mice
howev
infect
dose
viru
strain
differ
experi
difficult
compar
activ
drug
observ
effici
lycorin
infect
better
ribavirin
shown
determin
figur
evalu
mous
model
figur
furthermor
infect
selflimit
caus
sever
complic
patient
selfresolv
infect
model
infect
mice
develop
paralysi
dpi
symptom
basic
selflimit
within
dpi
expect
lycorin
treatment
abl
protect
infectedmic
paralysi
symptom
inhibit
replic
figur
meanwhil
found
lycorin
could
also
inhibit
infect
three
strain
strain
isol
clinic
specimen
differ
region
mainland
china
belong
genotyp
rd
cell
data
shown
demonstr
lycorin
effect
antivir
spectrum
strain
preval
mainland
china
summari
shown
lycorin
promis
drug
candid
treat
infect
potenti
applic
clinic
therapi
patient
may
contribut
control
epidem
asia
author
declar
compet
interest
jl
yy
carri
experi
except
patholog
analysi
draft
manuscript
yx
cm
carri
patholog
analysi
immunohistochem
stain
cq
particip
design
experi
edit
manuscript
lz
provid
overal
supervis
financi
support
prepar
final
version
manuscript
author
read
approv
final
manuscript
